It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the U.S. – his administration’s bid to boost ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer reaffirming its outlook for the full year but noting it has not factored in any potential impact from tariffs. Here to discuss what these results mean for the drug maker we've got Vamul Divan.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts polled by FactSet.

A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include ...

Like his Big Pharma peers, Pfizer (PFE ... said the company is already expecting a $150 million impact in 2025 from the current slate of tariffs but did not detail which products are impacted.

Pfizer CEO Albert Bourla on Tuesday said ... the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict ...

Singapore is negotiating with the U.S. to ease tariffs on pharmaceuticals and secure access to advanced chips amid shifting ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...